BDBM246258 US10183932, Example 164::US9434690, 164::US9822102, Example 164

SMILES COCCC(C(=O)Nc1ccc2c(c1)[nH][nH]c2=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C#N

InChI Key InChIKey=XCJQHVXBYDODIH-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 246258   

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 1.90nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 2.20nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 1.90nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 2.20nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 1.90nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246258(US9434690, 164 | US10183932, Example 164 | US98221...)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of human FXIa using Boc-Glu(OBzl)-Ala-Arg-AMC as substrate measured for 30 mins by fluorometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed